0000950170-24-075075.txt : 20240618 0000950170-24-075075.hdr.sgml : 20240618 20240618175942 ACCESSION NUMBER: 0000950170-24-075075 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240614 FILED AS OF DATE: 20240618 DATE AS OF CHANGE: 20240618 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Moran Sean F. CENTRAL INDEX KEY: 0001451495 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37348 FILM NUMBER: 241053376 MAIL ADDRESS: STREET 1: 10220-L OLD COLUMBIA ROAD CITY: COLUMBIA STATE: MD ZIP: 21046 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Corbus Pharmaceuticals Holdings, Inc. CENTRAL INDEX KEY: 0001595097 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464348039 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 RIVER RIDGE DRIVE CITY: NORWOOD STATE: MA ZIP: 02062 BUSINESS PHONE: 617-963-0103 MAIL ADDRESS: STREET 1: 500 RIVER RIDGE DRIVE CITY: NORWOOD STATE: MA ZIP: 02062 FORMER COMPANY: FORMER CONFORMED NAME: SAV Acquisition Corp DATE OF NAME CHANGE: 20131220 4 1 ownership.xml 4 X0508 4 2024-06-14 0001595097 Corbus Pharmaceuticals Holdings, Inc. CRBP 0001451495 Moran Sean F. C/O CORBUS PHARMACEUTICALS HOLDINGS, INC 500 RIVER RIDGE DRIVE NORWOOD MA 02062 false true false false Chief Financial Officer true Common Stock, par value $0.0001 per share 2024-06-14 4 M false 1567 30 A 50172 D Common Stock, par value $0.0001 per share 2024-06-14 4 S false 1567 49.8738 D 48605 D Common Stock, par value $0.0001 per share 2024-06-14 4 M false 7788 4.26 A 56393 D Common Stock, par value $0.0001 per share 2024-06-14 4 S false 7788 49.8738 D 48605 D Common Stock, par value $0.0001 per share 2024-06-17 4 M false 6730 14.10 A 55335 D Common Stock, par value $0.0001 per share 2024-06-17 4 S false 6730 46.774 D 48605 D Common Stock, par value $0.0001 per share 2024-06-18 4 M false 1958 30 A 50563 D Common Stock, par value $0.0001 per share 2024-06-18 4 S false 1958 42.1242 D 48605 D Options to purchase common stock 30 2024-06-14 4 M false 1567 0 D 2024-10-22 Common Stock 1567 1958 D Options to purchase common stock 4.26 2024-06-14 4 M false 7788 0 D 2024-02-13 2033-02-13 Common Stock 7788 23367 D Options to purchase common stock 14.10 2024-06-17 4 M false 6730 0 D 2023-02-01 2032-02-01 Common Stock 6730 11217 D Options to purchase common stock 30 2024-06-18 4 M false 1958 0 D 2024-10-22 Common Stock 1958 0 D This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.26 to $52.525 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.88 to $49.47 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $43.59 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested. The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024. The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 1, 2023, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2023. /s/Sean Moran 2024-06-18